Drug Development Technology-Updates The latest content updates from the www.drugdevelopment-technology.com web site http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ Drug Development Technology-Updates http://www.drugdevelopment-technology.com/content/images/logo_big.gif ePAT Automated Lab Reactor Optimised for 24/7 Data Capture http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/epat-automated-lab-reactor/ http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/epat-automated-lab-reactor/ Systag Systems presents ePAT, a cost-effective device for automation in the laboratory. Fri, 21 Apr 2017 15:28:00 GMT Benefits of Trehalose http://www.drugdevelopment-technology.com/downloads/whitepapers/organic/benefits-of-trehalose/ http://www.drugdevelopment-technology.com/downloads/whitepapers/organic/benefits-of-trehalose/ Products such as monoclonal antibodies (mAb), fusion proteins, peptides, vaccines, antibody drug conjugulates (ADC) and stem cells benefit from the stabilising effects of Trehalose. Fri, 21 Apr 2017 15:28:00 GMT Boehringer begins enrolment in Phase III trial of nintedanib for fibrosing lung diseases http://www.drugdevelopment-technology.com/news/newsboehringer-begins-enrolment-in-phase-iii-trial-of-nintedanib-for-fibrosing-lung-diseases-5792717 http://www.drugdevelopment-technology.com/news/newsboehringer-begins-enrolment-in-phase-iii-trial-of-nintedanib-for-fibrosing-lung-diseases-5792717 US-based Boehringer Ingelheim Pharmaceuticals has begun patient enrolment in the Phase III progressive fibrosing interstitial lung disease (PF-ILD) clinical trial of nintedanib to treat various progressive fibrosing lung diseases, excluding idiopathi… Thu, 20 Apr 2017 23:00:00 GMT M&As this week: Nivalis Therapeutics, Medidata Solutions http://www.drugdevelopment-technology.com/news/newsmas-this-week-nivalis-therapeutics-medidata-solutions-5792766 http://www.drugdevelopment-technology.com/news/newsmas-this-week-nivalis-therapeutics-medidata-solutions-5792766 Nautilus Merger Sub, a subsidiary of US-based pharmaceutical company, Nivalis Therapeutics, has reached a reverse takeover agreement to acquire Alpine Immune Sciences. Thu, 20 Apr 2017 23:00:00 GMT Clearside concludes enrolment in Phase I/II trial of CLS-TA to treat DME http://www.drugdevelopment-technology.com/news/newsclearside-concludes-enrolment-in-phase-iii-trial-of-cls-ta-to-treat-dme-5792739 http://www.drugdevelopment-technology.com/news/newsclearside-concludes-enrolment-in-phase-iii-trial-of-cls-ta-to-treat-dme-5792739 US-based biopharmaceutical firm Clearside Biomedical has concluded patient enrolment in the exploratory Phase I/II HULK trial of CLS-TA to treat diabetic macular edema (DME). Thu, 20 Apr 2017 23:00:00 GMT Deals this week: Galapagos, Bristol-Myers Squibb, Zymeworks http://www.drugdevelopment-technology.com/news/newsdeals-this-week-galapagos-bristol-myers-squibb-zymeworks-5792993 http://www.drugdevelopment-technology.com/news/newsdeals-this-week-galapagos-bristol-myers-squibb-zymeworks-5792993 Belgium-based clinical-stage biotechnology company Galapagos has announced the pricing for its proposed offering of American depository shares (ADS) to raise funds for its general corporate purposes, new and ongoing research and development (R&D) act… Thu, 20 Apr 2017 23:00:00 GMT Lion Biotechnologies and MD Anderson to investigate TIL therapy in solid tumour trials http://www.drugdevelopment-technology.com/news/newslion-biotechnologies-and-md-anderson-to-investigate-til-therapy-in-solid-tumour-trials-5792723 http://www.drugdevelopment-technology.com/news/newslion-biotechnologies-and-md-anderson-to-investigate-til-therapy-in-solid-tumour-trials-5792723 Lion Biotechnologies has entered a multi-year strategic alliance agreement with the University of Texas MD Anderson Cancer Center to investigate its tumour-infiltrating lymphocyte (TIL) therapy in multi-arm clinical trials to treat ovarian and pancre… Thu, 20 Apr 2017 23:00:00 GMT Abide doses first patient in Phase Ib trial of ABX-1431 to treat tourette syndrome http://www.drugdevelopment-technology.com/news/newsabide-doses-first-patient-in-phase-ib-trial-of-abx-1431-to-treat-tourette-syndrome-5790695 http://www.drugdevelopment-technology.com/news/newsabide-doses-first-patient-in-phase-ib-trial-of-abx-1431-to-treat-tourette-syndrome-5790695 US-based Abide Therapeutics has started dosing patients in a Phase Ib clinical trial of ABX-1431 for the treatment of tourette syndrome (TS). Wed, 19 Apr 2017 23:00:00 GMT Bavarian Nordic commences Phase II combination trial for prostate cancer http://www.drugdevelopment-technology.com/news/newsbavarian-nordic-commences-phase-ii-combination-trial-for-prostate-cancer-5791413 http://www.drugdevelopment-technology.com/news/newsbavarian-nordic-commences-phase-ii-combination-trial-for-prostate-cancer-5791413 Danish-based biotechnology firm Bavarian Nordic has commenced a Phase II clinical trial of Prostvac (rilimogene) in combination with Yervoy (ipilimumab) and / or Opdivo (nivolumab) to treat localised prostate cancer patients. Wed, 19 Apr 2017 23:00:00 GMT AbbVie's veliparib fails to meet primary endpoints in two Phase III combination trials http://www.drugdevelopment-technology.com/news/newsabbvies-veliparib-fails-to-meet-primary-endpoints-in-two-phase-iii-combination-trials-5791650 http://www.drugdevelopment-technology.com/news/newsabbvies-veliparib-fails-to-meet-primary-endpoints-in-two-phase-iii-combination-trials-5791650 AbbVie has reported top-line results from two Phase III clinical trials of its veliparib in combination with chemotherapy regimen to treat squamous non-small-cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Wed, 19 Apr 2017 23:00:00 GMT GeNeuro starts Phase IIa trial of GNbAC1 in Australia to treat Type 1 diabetes http://www.drugdevelopment-technology.com/news/newsgeneuro-starts-phase-iia-trial-of-gnbac1-in-australia-to-treat-type-1-diabetes-5789726 http://www.drugdevelopment-technology.com/news/newsgeneuro-starts-phase-iia-trial-of-gnbac1-in-australia-to-treat-type-1-diabetes-5789726 Swiss-based GeNeuro has started a Phase IIa clinical trial of GNbAC1 in Australia for the treatment of Type 1 diabetes (T1D) patients. Tue, 18 Apr 2017 23:00:00 GMT Gamlen Study: Breaking Anisotropic Rod-Shaped Particles http://www.drugdevelopment-technology.com/downloads/whitepapers/lab_equipment/gamlen-study/ http://www.drugdevelopment-technology.com/downloads/whitepapers/lab_equipment/gamlen-study/ Gamlen presents a study conducted by V. Penkavova1, L. Kulaviak1, M.C. Ruzicka1, M. Puncochar, and P. Zamostny on the 'Beaking of Anisotropic Rod-Saped Particles'. Tue, 18 Apr 2017 23:00:00 GMT Novartis and Allergan to conduct Phase IIb trial to treat NASH http://www.drugdevelopment-technology.com/news/newsnovartis-allergan-partner-to-conduct-phase-iib-trial-to-treat-nash-5789313 http://www.drugdevelopment-technology.com/news/newsnovartis-allergan-partner-to-conduct-phase-iib-trial-to-treat-nash-5789313 Swiss healthcare firm Novartis has entered a clinical trial agreement with Irish pharmaceutical company Allergan to conduct a Phase IIb trial of FXR agonist and cenicriviroc (CVC) combination to treat non-alcoholic steatohepatitis (NASH). Tue, 18 Apr 2017 23:00:00 GMT Immunovaccine starts dosing in Phase Ib/II trial of DPX-E7 to treat HPV-related cancers http://www.drugdevelopment-technology.com/news/newsimmunovaccine-starts-dosing-in-phase-ibii-trial-of-dpx-e7-to-treat-hpv-related-cancers-5790299 http://www.drugdevelopment-technology.com/news/newsimmunovaccine-starts-dosing-in-phase-ibii-trial-of-dpx-e7-to-treat-hpv-related-cancers-5790299 Canadian-based biopharmaceutical company Immunovaccine has started dosing patients in a Phase Ib/II trial of its vaccine DPX-E7 for the treatment of incurable human papillomavirus (HPV) related oropharyngeal, cervical and anal cancers. Tue, 18 Apr 2017 23:00:00 GMT OncoMed's tarextumab fails to meet endpoints in Phase II trial for small-cell lung cancer http://www.drugdevelopment-technology.com/news/newsoncomeds-tarextumab-does-not-meet-endpoints-in-phase-ii-trial-for-small-cell-lung-cancer-5789072 http://www.drugdevelopment-technology.com/news/newsoncomeds-tarextumab-does-not-meet-endpoints-in-phase-ii-trial-for-small-cell-lung-cancer-5789072 US-based OncoMed Pharmaceuticals' tarextumab (anti-Notch2/3, OMP-59R5) has not met the endpoints in a Phase II clinical trial to treat patients with extensive-stage, small-cell lung cancer. Mon, 17 Apr 2017 23:00:00 GMT SYSTAG Systems Technik-Automation Systems for Small-Molecule Drug and API Development http://www.drugdevelopment-technology.com/contractors/delivery/systag-systems/ http://www.drugdevelopment-technology.com/contractors/delivery/systag-systems/ SYSTAG provides specialist innovative tools for automating chemical synthesis reactions for the pharmaceutical and fine chemicals industry.From laboratory-scale to mini-pilot, SYSTAG's conceptual and... Mon, 17 Apr 2017 23:00:00 GMT Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia http://www.drugdevelopment-technology.com/projects/ingrezza-valbenazine-for-the-treatment-of-tardive-dyskinesia/ http://www.drugdevelopment-technology.com/projects/ingrezza-valbenazine-for-the-treatment-of-tardive-dyskinesia/ Ingrezza (valbenazine) is first and only US Food and Drug Administration (FDA) approved vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with Tardive dyskinesia (TD). Mon, 17 Apr 2017 23:00:00 GMT Medicenna begins dosing in Phase IIb trial of MDNA55 to treat rGB http://www.drugdevelopment-technology.com/news/newsmedicenna-begins-dosing-in-phase-iib-trial-of-mdna55-to-treat-rgb-5788069 http://www.drugdevelopment-technology.com/news/newsmedicenna-begins-dosing-in-phase-iib-trial-of-mdna55-to-treat-rgb-5788069 Medicenna Therapeutics' subsidiary Medicenna BioPharma has begun dosing patients in the Phase IIb trial of its MDNA55 to treat recurrent glioblastoma (rGB). Mon, 17 Apr 2017 23:00:00 GMT Genentech reports positive interim data from Phase III trial of emicizumab for haemophilia A http://www.drugdevelopment-technology.com/news/newsgenentech-reports-positive-interim-data-from-phase-iii-trial-of-emicizumab-for-hemophilia-a-5788120 http://www.drugdevelopment-technology.com/news/newsgenentech-reports-positive-interim-data-from-phase-iii-trial-of-emicizumab-for-hemophilia-a-5788120 Roche's biotechnology subsidiary Genentech has reported positive interim results from the Phase III HAVEN 2 clinical trial of emicizumab for the treatment of children with haemophilia A and inhibitors to factor VIII. Mon, 17 Apr 2017 23:00:00 GMT Reasons to Upgrade to a MicroCal PEAQ-DSC System http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/upgrade-microcal-peaq-dsc-system/ http://www.drugdevelopment-technology.com/downloads/whitepapers/delivery/upgrade-microcal-peaq-dsc-system/ Differential Scanning Calorimetry (DSC) is a tool for protein stability characterisation in drug development. Its data is used to advance stable and developable proteins into the pipeline, while optimising process and formulation conditions to mainta… Sun, 16 Apr 2017 23:00:00 GMT